Home›Companies›Biotech & Pharma›Coeurative

Coeurative, Inc.

Develops a drug for people with angina caused by heart disease.

Updated Nov 9, 2026·Latest SEC filing Oct 13, 2026·Suggest an edit

About Coeurative

Coeurative is a private company based in Roanoke, Virginia. It has reported $1,120,000 raised in six offerings on Form D since May 2013. Its chief executive is John Schmedtje, Jr..

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
Sep 27, 2026Oct 13, 2026$100,000of $2.0M target1$100KEquityRule 506(b)Form D ↗
Sep 26, 2023Oct 11, 2023amended Apr 2, 2024$300,000of $3.7M target2$150KEquityRule 506(b)Form D/A ↗1 earlier filing
May 8, 2021Jun 2, 2021amended Sep 29, 2022$400,000of $500K target1$400KEquityRule 506(b)Form D/A ↗1 earlier filing
Sep 23, 2020Oct 7, 2020$100,000of $500K target1$100KEquityRule 506(b)Form D ↗
Oct 30, 2017Nov 3, 2017$100,000of $1.0M target1$100KEquityRule 506(b)Form D ↗
Jan 31, 2013May 20, 2013$120,000of $2.0M target2$60,000Equity06Form D ↗
Total, six offerings$1,120,000

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Coeurative's Form D filed Oct 13, 2026.

JJ
John Schmedtje, Jr.
President and Chief Executive Officer, director

Earlier filings also listed John Schmedtje, J.r (executive officer and director, last listed May 2013).

Sources

  1. SECCoeurative, Inc. Form D, filed Oct 11, 2023
  2. SECCoeurative, Inc. Form D, filed Jun 2, 2021
  3. SECCoeurative, Inc. filing history